Perigon Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.9M | Sell |
110,052
-1,777
| -2% | -$394K | 0.43% | 44 |
|
|
2025
Q4 | $25.6M | Buy |
111,829
+721
| +0.6% | +$164K | 0.46% | 44 |
|
|
2025
Q3 | $25.7M | Buy |
111,108
+3,905
| +4% | +$795K | 0.52% | 37 |
|
|
2025
Q2 | $19.9M | Buy |
107,203
+983
| +0.9% | +$183K | 0.46% | 44 |
|
|
2025
Q1 | $22.3M | Sell |
106,220
-5,077
| -5% | -$987K | 0.57% | 33 |
|
|
2024
Q4 | $19.3M | Buy |
111,297
+17,432
| +19% | +$3.2M | 0.47% | 36 |
|
|
2024
Q3 | $18.5M | Buy |
93,865
+433
| +0.5% | +$80.8K | 0.49% | 36 |
|
|
2024
Q2 | $16M | Sell |
93,432
-3,597
| -4% | -$596K | 0.46% | 44 |
|
|
2024
Q1 | $17.7M | Sell |
97,029
-5,660
| -6% | -$975K | 0.54% | 37 |
|
|
2023
Q4 | $15.9M | Buy |
102,689
+15,053
| +17% | +$2.19M | 0.52% | 41 |
|
|
2023
Q3 | $13.1M | Buy |
87,636
+1,522
| +2% | +$223K | 0.53% | 40 |
|
|
2023
Q2 | $11.6M | Buy |
86,114
+45,977
| +115% | +$6.74M | 0.46% | 49 |
|
|
2023
Q1 | $6.4M | Buy |
40,137
+248
| +0.6% | +$37.9K | 0.36% | 67 |
|
|
2022
Q4 | $6.45M | Buy |
39,889
+9,210
| +30% | +$1.41M | 0.4% | 57 |
|
|
2022
Q3 | $4.12M | Buy |
30,679
+4,412
| +17% | +$633K | 0.36% | 61 |
|
|
2022
Q2 | $4.02M | Buy |
26,267
+804
| +3% | +$123K | 0.34% | 69 |
|
|
2022
Q1 | $4.13M | Buy |
25,463
+2,931
| +13% | +$426K | 0.29% | 74 |
|
|
2021
Q4 | $3.05M | Buy |
22,532
+2,121
| +10% | +$251K | 0.22% | 93 |
|
|
2021
Q3 | $2.2M | Buy |
20,411
+89
| +0.4% | +$10.2K | 0.19% | 102 |
|
|
2021
Q2 | $2.29M | Buy |
20,322
+667
| +3% | +$75.1K | 0.2% | 94 |
|
|
2021
Q1 | $2.13M | Buy |
19,655
+2,300
| +13% | +$246K | 0.22% | 94 |
|
|
2020
Q4 | $1.86M | Sell |
17,355
-2,081
| -11% | -$200K | 0.22% | 83 |
|
|
2020
Q3 | $1.7M | Sell |
19,436
-148
| -0.8% | -$13.9K | 0.24% | 77 |
|
|
2020
Q2 | $1.92M | Buy |
19,584
+3,895
| +25% | +$343K | 0.3% | 65 |
|
|
2020
Q1 | $1.25M | Buy |
15,689
+2,136
| +16% | +$182K | 0.23% | 85 |
|
|
2019
Q4 | $1.21M | Buy |
13,553
+289
| +2% | +$24K | 0.25% | 77 |
|
|
2019
Q3 | $988K | Buy |
13,264
+67
| +0.5% | +$4.59K | 0.23% | 77 |
|
|
2019
Q2 | $960K | Sell |
13,197
-95
| -0.7% | -$7.47K | 0.22% | 78 |
|
|
2019
Q1 | $1.07M | Buy |
13,292
+6
| +0% | +$491 | 0.25% | 71 |
|
|
2018
Q4 | $1.09M | Sell |
13,286
-29
| -0.2% | -$2.55K | 0.28% | 65 |
|
|
2018
Q3 | $1.26M | Buy |
13,315
+1,600
| +14% | +$152K | 0.31% | 58 |
|
|
2018
Q2 | $1.08M | Sell |
11,715
-215
| -2% | -$21K | 0.33% | 63 |
|
|
2018
Q1 | $1.13M | Buy |
11,930
+7
| +0.1% | +$769 | 0.42% | 51 |
|
|
2017
Q4 | $1.15M | Buy |
11,923
+100
| +0.8% | +$9.43K | 0.43% | 48 |
|
|
2017
Q3 | $1.05M | Sell |
11,823
-485
| -4% | -$36.9K | 0.34% | 66 |
|
|
2017
Q2 | $892K | Hold |
12,308
| – | – | 0.19% | 119 |
|
|
2017
Q1 | $802K | Buy |
12,308
+355
| +3% | +$22.3K | 0.17% | 125 |
|
|
2016
Q4 | $757K | Buy |
11,953
+230
| +2% | +$14K | 0.17% | 132 |
|
|
2016
Q3 | $739K | Buy |
11,723
+125
| +1% | +$8.09K | 0.19% | 109 |
|
|
2016
Q2 | $718K | Buy |
11,598
+6,665
| +135% | +$406K | 0.19% | 114 |
|
|
2016
Q1 | $28K | Sell |
4,933
-11,100
| -69% | -$619K | 0.01% | 216 |
|
|
2015
Q4 | $950K | Sell |
16,033
-3,503
| -18% | -$202K | 0.26% | 103 |
|
|
2015
Q3 | $1.06M | Sell |
19,536
-353
| -2% | -$23K | 0.32% | 88 |
|
|
2015
Q2 | $1.34M | Buy |
19,889
+387
| +2% | +$25.3K | 0.35% | 77 |
|
|
2015
Q1 | $1.14M | Buy |
19,502
+175
| +0.9% | +$10.6K | 0.31% | 79 |
|
|
2014
Q4 | $1.26M | Buy |
19,327
+373
| +2% | +$23.5K | 0.38% | 66 |
|
|
2014
Q3 | $1.09M | Buy |
18,954
+5,174
| +38% | +$287K | 0.33% | 78 |
|
|
2014
Q2 | $778K | Buy |
13,780
+2,305
| +20% | +$121K | 0.22% | 98 |
|
|
2014
Q1 | $590K | Buy |
11,475
+175
| +2% | +$8.84K | 0.32% | 69 |
|
|
2013
Q4 | $596K | Buy |
+11,300
| New | +$555K | 0.33% | 65 |
|
Other funds holding ABBV
VCM
VPM
Perigon Wealth Management's ABBV Position: Q1 2026 in Review
Perigon Wealth Management reduced its AbbVie (ABBV) stake by 1.6% in Q1 2026, selling an estimated $394K and leaving 110,052 shares worth $23.9M. The position accounts for 0.43% of the portfolio, ranked #44.
Perigon Wealth Management first reported a position in ABBV in Q4 2013 and has held it in 50 quarters since. The position peaked at $25.7M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Perigon Wealth Management held 110,052 shares of AbbVie worth $23.9M as of Q1 2026.
- Perigon Wealth Management sold 1,777 AbbVie shares in Q1 2026, an estimated $394K.
- AbbVie made up 0.43% of Perigon Wealth Management's portfolio in Q1 2026, its #44 holding.
- Perigon Wealth Management first reported a position in AbbVie in Q4 2013 and has held it in 50 quarters since.
- Perigon Wealth Management's AbbVie position peaked at $25.7M in Q3 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Perigon Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.